Valuation: Becton, Dickinson and Company

Market Cap 49.29B 42.98B 40.58B 36.85B 69.04B 4,729B 69.33B 486B 188B 2,404B 185B 181B 7,736B P/E 2026 *
34.9x
P/E 2027 * 19.4x
Enterprise Value 65.17B 56.83B 53.66B 48.73B 91.29B 6,253B 91.68B 643B 248B 3,179B 245B 239B 10,230B EV / Sales 2026 *
3.38x
EV / Sales 2027 * 3.2x
Free-Float
73.18%
Yield 2026 *
2.17%
Yield 2027 * 2.21%
Manager TitleAgeSince
Chief Executive Officer 53 2020-01-27
Director of Finance/CFO 44 2025-12-04
Compliance Officer - 2023-01-31
Director TitleAgeSince
Director/Board Member 75 2002-09-23
Director/Board Member 71 2010-07-25
Chairman 53 2021-04-27
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-18.36% - - 49.29B
-0.63%-0.95%-25.26%+3.22% 178B
-0.17%-2.04%-2.89%+14.21% 118B
+0.35%-5.01%+7.31%+67.58% 58.92B
-0.10%-1.23%-3.16%-31.84% 49.29B
-0.22%-0.37%+10.27%+42.75% 48.17B
-0.34%+4.96%+27.87%-0.22% 33.72B
+0.52%-2.56% - - 27.76B
-0.02%+2.45%+44.28%-2.78% 25.5B
+1.26%+9.13%+8.63%-13.45% 22.1B
Average +0.14%+1.65%+8.38%+9.93% 62.32B
Weighted average by Cap. -0.06%+0.95%-3.37%+11.90%

Financials

2026 *2027 *
Net sales 19.26B 16.8B 15.86B 14.4B 26.98B 1,848B 27.09B 190B 73.31B 940B 72.35B 70.75B 3,023B 19.73B 17.21B 16.25B 14.75B 27.64B 1,893B 27.76B 195B 75.1B 963B 74.13B 72.48B 3,097B
Net income 1.44B 1.25B 1.18B 1.07B 2.01B 138B 2.02B 14.17B 5.47B 70.09B 5.4B 5.28B 226B 2.34B 2.04B 1.93B 1.75B 3.28B 224B 3.29B 23.07B 8.9B 114B 8.79B 8.59B 367B
Net Debt 15.88B 13.85B 13.08B 11.88B 22.25B 1,524B 22.35B 157B 60.46B 775B 59.67B 58.35B 2,493B 13.95B 12.17B 11.49B 10.43B 19.54B 1,339B 19.63B 138B 53.1B 681B 52.41B 51.25B 2,190B
Logo Becton, Dickinson and Company
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical management systems (52.4%): medication delivery systems, pharmaceutical systems, advanced patient monitoring systems, etc.; - interventional medical equipment (23.9%): surgical instruments, urological care products, etc.; - diagnostic materials and clinical research and development tools (23.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, tools for studying genes and culturing cells, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (58.6%), Europe/Middle East/Africa (21.6%), Asia (14.2%) and other (5.6%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!